JAIRO GOMEZ: Open Payments
NPI 1417055104 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,151 in 77 payments from 10 companies in 2025. Trend: 2023 $2,762 · 2024 $3,018 · 2025 $3,151
Food & beverage: $3,151
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 13 | $775 |
| Otsuka America Pharmaceutical, Inc. | 23 | $693 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $402 |
| E.R. Squibb & Sons, L.L.C. | 14 | $381 |
| Alkermes, Inc. | 3 | $266 |
| ABBVIE INC. | 3 | $159 |
| Neurocrine BioSciences, Inc. | 2 | $157 |
| Teva Pharmaceuticals USA, Inc. | 5 | $131 |
| Janssen Biotech, Inc. | 1 | $123 |
| Vanda Pharmaceuticals Inc. | 3 | $65 |
Products named: INVEGA SUSTENNA, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, REXULTI, VRAYLAR, INGREZZA, ABILIFY MAINTENA.
Industry payments across CA — which companies pay providers there.
